Resource Summary Report

Generated by dkNET on Sep 4, 2026

TMD8

RRID:CVCL_A442
Type: Cell Line

Proper Citation

RRID:CVCL_A442

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_A442

Proper Citation: RRID:CVCL_A442

Description: Cell line TMD8 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma activated B-cell type

Defining Citation: PMID:16780947, PMID:20054396, PMID:21179087, PMID:23257783, PMID:23292937, PMID:25485619, PMID:26589293, PMID:26787899, PMID:27566572, PMID:29416618, PMID:29666304

Comments: Miscellaneous: STR profile from personal communication of Gachova, Daniela., Characteristics: Genetically heterogeneous, consists of 3 subclones (PubMed=27566572)., Population: Japanese.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TMD8

Synonyms: TMD-8, Tokyo Medical and Dental university 8

Cross References: EFO:EFO_0006496, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-4956, BioGRID_ORCS_Cell_line:748, cancercelllines:CVCL_A442, ChEMBL-Cells:CHEMBL4295480, ChEMBL-Targets:CHEMBL4296503, CLS:305729, Cosmic:1486587, Cosmic:1945194, Cosmic:2129635, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM1059801, GEO:GSM1374963, GEO:GSM1527304, GEO:GSM1527305, GEO:GSM1527306, GEO:GSM1527307, GEO:GSM1527308, GEO:GSM1527309, GEO:GSM1890021, GEO:GSM1890022, GEO:GSM1890023,

GEO:GSM1890024, GEO:GSM2037048, GEO:GSM2037049, PharmacoDB:TMD8_1600_2019, Progenetix:CVCL_A442, PubChem_Cell_line:CVCL_A442, Wikidata:Q54972694

ID: CVCL_A442

Record Creation Time: 20220427T221631+0000

Record Last Update: 20260904T015825+0000

Ratings and Alerts

No rating or validation information has been found for TMD8.

No alerts have been found for TMD8.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Demel UM, et al. (2026) Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e11449.

Wang B, et al. (2026) Axes of biological variation in diffuse large B cell lymphoma. Cancer cell.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Calaud C, et al. (2026) Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma. Blood neoplasia, 3(2), 100214.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Manara P, et al. (2025) Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy. Cancer research.

Pieper NM, et al. (2024) Inhibition of bromodomain and extra-terminal proteins targets constitutively active NF?B and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell communication and signaling :

CCS, 22(1), 415.

Phelan JD, et al. (2024) Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. Cancer cell, 42(2), 238.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Wu Y, et al. (2024) Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase-targeted protein degrader BGB-16673. British journal of pharmacology.

Li W, et al. (2024) Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling. Molecular cancer therapeutics, 23(1), 35.

Eken JA, et al. (2024) Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. The Journal of experimental medicine, 221(5).

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Delage L, et al. (2023) BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1. Blood, 141(10), 1209.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. Cancer discovery, 13(8), 1862.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer discovery, 13(1), 216.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. International journal of cancer, 148(1), 150.